Check patentability & draft patents in minutes with Patsnap Eureka AI!

Design, preparation and application of trispecific antibody

A specific, antibody-based technology, applied in the direction of antibodies, anti-tumor drugs, and the use of vectors to introduce foreign genetic material, etc., to achieve the effects of prolonging the half-life, avoiding neutropenia, and directly inhibiting tumor growth

Pending Publication Date: 2022-07-29
NANJING JSIAMA BIOPHARMACEUTICALS LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Bispecific antibodies targeting Her2 and CD47 have been reported, but trispecific antibodies targeting Her2-CD47-CD16a have not been reported, which belongs to First-In-Class

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Design, preparation and application of trispecific antibody
  • Design, preparation and application of trispecific antibody
  • Design, preparation and application of trispecific antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Binding of trispecific antibodies to Her2 protein by ELISA

[0096] Coated with different concentrations (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0) Her2 protein (10004-H08H1, Yiqiao Shenzhou) ), 100ul / well at 4°C overnight; blocked with 3% nonfat milk powder at 37°C for 1h; add 1ug / ml trispecific antibody and 100ul of other control samples to each well, incubate at 37°C for 1h; then add goat anti-human IgG / HRP, Incubate at 37°C for 1h, and read the OD450 on a microplate reader after 10min of color development. see the results image 3 .

Embodiment 2

[0098] Detection of binding of trispecific antibodies to CD47 protein by ELISA

[0099] Coated with different concentrations (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0) CD47 protein (12283-H08H, Yiqiao Shenzhou) ), 100ul / well overnight at 4°C; blocked with 3% nonfat milk powder at 37°C for 1h; add 100ul of 1ug / ml trispecific antibodies to each well, incubate at 37°C for 1h; then add goat anti-human IgG / HRP, incubate at 37°C for 1h , after 10min of color development, read the OD450 on the microplate reader. see the results Figure 4 .

Embodiment 3

[0101] ELISA to detect the binding of trispecific antibodies to CD16a protein

[0102]Coated with different concentrations (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0) CD16a protein (10389-H08C, Yiqiao Shenzhou) ), 100ul / well overnight at 4°C; blocked with 3% nonfat milk powder at 37°C for 1h; add 100ul of 1ug / ml trispecific antibodies to each well, incubate at 37°C for 1h; then add goat anti-human IgG / HRP, incubate at 37°C for 1h , after 10min of color development, read the OD450 on the microplate reader. see the results Figure 5 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Cell numberaaaaaaaaaa
Login to View More

Abstract

The invention provides design, a preparation method and application of a tri-specific antibody. The tri-specific antibody disclosed by the invention comprises (a) an anti-Her2 monoclonal antibody Herceptin, (b) an anti-CD16a (FcgRIIIa) single-chain antibody scFv, (c) SIRPa D1 protein and (d) a flexible linker; the C end of a heavy chain of the antibody Herceptin is connected with an anti-CD16a single-chain antibody through a linker, and the C end of a light chain of the antibody Herceptin is connected with SIRPa D1 through a linker; the Fc segment of the antibody is modified so as to change the binding capacity of the Fc segment with a receptor and prolong the half-life period of the protein; the SIRPa D1 is combined with the CD47 ligand, so that tumor cells capable of expressing CD47 in a targeting manner can be obtained; meanwhile, a'don't eat me) 'signal can be blocked, so that macrophages are activated to phagocytize tumor cells; the method comprises the following steps: specifically combining with NK (Natural Killing) cells by virtue of anti-CD16a (anti-CD16a); therefore, macrophages and NK cells in a tumor microenvironment are recruited through SIRPa and anti-CD16a to kill tumor cells; according to the present invention, the specificity of anti-CD16a is ensured, and the side effect (Neutropenia) caused by the combination with the CD16b on the surface of the neutrophil can not be caused.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the design, preparation and use of a trispecific antibody. Background technique [0002] With the continuous development and deepening of oncology and immunology, tumor immunotherapy has become the most cutting-edge treatment in the field of anti-tumor. At present, the main research direction of tumor immunotherapy at home and abroad is immune checkpoint inhibitors. CD47 has always been considered by the industry to be the most important target in the field of tumor immunity after PD-1 / PD-L1. At present, there are countless candidate drugs targeting CD47 in the preclinical and clinical development stages around the world. There are no approved anti-CD47 therapies. [0003] CD47 is widely expressed on the surface of a variety of cancer cells, but also on the surface of red blood cells to protect itself from phagocytosis. This means that drugs targeting CD47 will ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/46C12N15/85C12N15/66C12N15/64A61K39/395A61P35/00
CPCC07K16/32C07K16/283C07K16/2896C12N15/85A61P35/00C07K2317/31C07K2317/622C07K2317/56C07K2317/52C07K2317/92C07K2317/76C12N2800/107
Inventor 刘立明韩镇康平
Owner NANJING JSIAMA BIOPHARMACEUTICALS LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com